Across
- 3. immunotherapy in papillary driven MET RCC in Calypso trial
- 4. HbA1c cutoff for exclusion from trials of Enfortumab Vedotin
- 7. Immunotherapy evaluated in RENOTORCH trial along with axitinib
- 10. Number of months post cystectomy for which testing of ctDNA was carried out in ImVigor011
- 11. Approximate % of complete response of patients who received Nadofaragene firadenovec in high risk BCG unresponsive NMIBC
Down
- 1. Addition of __________ to Enzalutamide in mCRPC with bone mets improved PFS in PEACE-3
- 2. MRI scoring system used to standardize the staging of bladder cancer by evaluating the likelihood of muscle invasion (detrusor muscle)
- 3. ARASAFE trial tested a 2 weekly v/s 3 weekly schedule of which drug
- 5. Trial which evaluated Belzutifan v/s Everolimus in clear cell RCC
- 6. NAPSTER evaluated addition of ____ pembrolizumab as neoadjuvant therapy in locally advanced RCC
- 8. Biomarker used for inclusion in CAPITELLO-281 trial
- 9. PSMA radioligand alpha emitter